ImpriMed
A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.
$10MSeries A2 bridge
ParticipantSS
Samsung Securities
Activity from announced rounds
Activity in this selectionOct 18, 2026 · Jul 21, 2026
Samsung Securities is the securities company identified by LinqAlpha and as a new investor by ImpriMed.
Recorded funding activity
LinqAlpha develops research agents for institutional investing. ImpriMed combines live-cell drug testing with clinical data. The corporate investor remains distinct from Samsung Electronics and Samsung Ventures.
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $10M 1 disclosed · full round size, not this investor’s share